Please try another search
Kite Pharma, Inc. develops novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. In addition, it engages in developing T cell receptor-based therapies that target self-antigens, viral antigens, and neo-antigens. The company was incorporated in 2009 and is based in Santa Monica, California with additional locations in Santa Monica, El Segundo, Oceanside, Emeryville, California; Frederick, Maryland; United Kingdom; and the Netherlands. Kite Pharma, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review